(株)ミズホメディーの貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証STD | 医薬品 | 4595/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2017/10/13 | 日証協 | 116,300株 | -15.72% | 17,100株 | -33.2% | 216,688株 | +118.02% | 131,400株 | +1393.18% |
2017/10/06 | 日証協 | 138,000株 | +9.35% | 25,600株 | +241.33% | 99,388株 | +4.52% | 8,800株 | +237.94% |
2017/09/29 | 日証協 | 126,200株 | -2.47% | 7,500株 | -56.35% | 95,092株 | -1.55% | 2,604株 | +544.55% |
2017/09/22 | 日証協 | 129,400株 | +1.09% | 17,184株 | -7.11% | 96,588株 | +0.52% | 404株 | -88.79% |
2017/09/15 | 日証協 | 128,000株 | +9.31% | 18,500株 | -40.13% | 96,088株 | -55.39% | 3,604株 | -86.08% |
2017/09/08 | 日証協 | 117,100株 | +8.23% | 30,900株 | +77.59% | 215,388株 | +2.23% | 25,900株 | +1026.09% |
2017/09/01 | 日証協 | 108,200株 | -1.81% | 17,400株 | +123.08% | 210,688株 | -0.47% | 2,300株 | -55.8% |
2017/08/25 | 日証協 | 110,200株 | -1.61% | 7,800株 | -63.21% | 211,692株 | -0.24% | 5,204株 | -82.2% |
2017/08/18 | 日証協 | 112,000株 | -10.9% | 21,200株 | +175.32% | 212,192株 | +1.6% | 29,244株 | +306.17% |
2017/08/10 | 日証協 | 125,700株 | +1.7% | 7,700株 | -9.41% | 208,848株 | +0.87% | 7,200株 | +1.41% |
2017/08/04 | 日証協 | 123,600株 | +2.06% | 8,500株 | +117.95% | 207,048株 | +0.54% | 7,100株 | +173.08% |
2017/07/28 | 日証協 | 121,100株 | -6.34% | 3,900株 | -89.2% | 205,943株 | -1.15% | 2,600株 | -65.33% |
2017/07/21 | 日証協 | 129,300株 | +16.49% | 36,100株 | -37.11% | 208,343株 | +5.31% | 7,500株 | -26.05% |
2017/07/14 | 日証協 | 111,000株 | -5.92% | 57,400株 | -54.26% | 197,847株 | -2.63% | 10,142株 | -94.21% |
2017/07/07 | 日証協 | 117,984株 | +47.11% | 125,500株 | +41.83% | 203,199株 | +799.11% | 175,224株 | +421.5% |
2017/06/30 | 日証協 | 80,200株 | +28.12% | 88,484株 | +1020.05% | 22,600株 | -49.73% | 33,600株 | +380% |
2017/06/23 | 日証協 | 62,600株 | +3.64% | 7,900株 | +14.49% | 44,957株 | -58.27% | 7,000株 | -89.69% |
2017/06/16 | 日証協 | 60,400株 | 0% | 6,900株 | -73.66% | 107,727株 | +128.58% | 67,900株 | +2724.46% |
2017/06/09 | 日証協 | 60,400株 | -38.05% | 26,200株 | -33.84% | 47,128株 | -24.02% | 2,404株 | -67.51% |
※株式分割は考慮していませんのでご注意ください。
Page Top